Man Group PLC Revance Therapeutics, Inc. Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Man Group PLC holds 300,000 shares of RVNC stock, worth $771,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares

300,000

Holding current value

$771,000

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.57 - $2.57 $771,000 - $771,000	300,000 New	300,000 $771,000
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $285,820 - $624,719	24,919 New	24,919 $285,000
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $4.59 Million - $8.81 Million	249,774 New	249,774 $8.05 Million
Q3 2021 Nov 15, 2021	SELL	$25.78 - $33.21 $427,948 - $551,286	-16,600 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$26.8 - $31.84 $444,880 - $528,544	16,600 New	16,600 $492,000
Q3 2018 Nov 14, 2018	SELL	$23.55 - $30.1 $1.05 Million - $1.34 Million	-44,500 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$27.45 - $33.35 $2,745 - $3,335	-100 Reduced 0.22%	44,500 $1.22 Million
Q1 2018 May 15, 2018	BUY	$29.15 - $37.4 $1.3 Million - $1.67 Million	44,600 New	44,600 $1.37 Million

Others Institutions Holding RVNC

# of Institutions

233

Shares Held

83.1M

Call Options Held

680K

Put Options Held

896K

Black Rock Inc. New York, NY

8.57M
Shares

$22 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.73M
Shares

$14.7 Million
0.0% of portfolio
Franklin Resources Inc San Mateo, CA

4.78M
Shares

$12.3 Million
0.0% of portfolio
Fil LTD Hamilton, D0

4.19M
Shares

$10.8 Million
0.01% of portfolio
Alpine Associates Management Inc. Englewood Cliffs, NJ

4.16M
Shares

$10.7 Million
0.49% of portfolio

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account